Cargando…

DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.

In 82 patients with stage III malignant melanoma, the primary tumours were investigated by DNA flow cytometry. The tumours were classified as DNA diploid (n = 36), tetraploid (n = 11) and aneuploid (n = 35). By univariate analysis a significant correlation with post-recurrence survival was found for...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlsson, M., Boeryd, B., Carstensen, J., Kågedal, B., Bratel, A. T., Wingren, S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968202/
https://www.ncbi.nlm.nih.gov/pubmed/8427773
_version_ 1782134689114357760
author Karlsson, M.
Boeryd, B.
Carstensen, J.
Kågedal, B.
Bratel, A. T.
Wingren, S.
author_facet Karlsson, M.
Boeryd, B.
Carstensen, J.
Kågedal, B.
Bratel, A. T.
Wingren, S.
author_sort Karlsson, M.
collection PubMed
description In 82 patients with stage III malignant melanoma, the primary tumours were investigated by DNA flow cytometry. The tumours were classified as DNA diploid (n = 36), tetraploid (n = 11) and aneuploid (n = 35). By univariate analysis a significant correlation with post-recurrence survival was found for time to first metastasis, DNA-ploidy and S-phase fraction. By multivariate analysis, significant prognostic variables were found to be the time to first metastasis (P = 0.006), and ploidy (P = 0.011). Patients with diploid melanomas and a long recurrence-free interval had a median post-recurrence survival time of 45 months compared to 18 months in patients with DNA aneuploid tumours and an early recurrence. The S-phase could be estimated in 47 primary melanomas and was found to be a significant prognostic variable (P = 0.017). The median survival was 45 months for patients with melanomas with a S-phase fraction below 5%, and 19 months for melanomas with S-phase above 10%. The prognostic value of the S-phase remained significant even after adjustment for recurrence-free interval and DNA ploidy.
format Text
id pubmed-1968202
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19682022009-09-10 DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease. Karlsson, M. Boeryd, B. Carstensen, J. Kågedal, B. Bratel, A. T. Wingren, S. Br J Cancer Research Article In 82 patients with stage III malignant melanoma, the primary tumours were investigated by DNA flow cytometry. The tumours were classified as DNA diploid (n = 36), tetraploid (n = 11) and aneuploid (n = 35). By univariate analysis a significant correlation with post-recurrence survival was found for time to first metastasis, DNA-ploidy and S-phase fraction. By multivariate analysis, significant prognostic variables were found to be the time to first metastasis (P = 0.006), and ploidy (P = 0.011). Patients with diploid melanomas and a long recurrence-free interval had a median post-recurrence survival time of 45 months compared to 18 months in patients with DNA aneuploid tumours and an early recurrence. The S-phase could be estimated in 47 primary melanomas and was found to be a significant prognostic variable (P = 0.017). The median survival was 45 months for patients with melanomas with a S-phase fraction below 5%, and 19 months for melanomas with S-phase above 10%. The prognostic value of the S-phase remained significant even after adjustment for recurrence-free interval and DNA ploidy. Nature Publishing Group 1993-01 /pmc/articles/PMC1968202/ /pubmed/8427773 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Karlsson, M.
Boeryd, B.
Carstensen, J.
Kågedal, B.
Bratel, A. T.
Wingren, S.
DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
title DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
title_full DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
title_fullStr DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
title_full_unstemmed DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
title_short DNA ploidy and S-phase in primary malignant melanoma as prognostic factors for stage III disease.
title_sort dna ploidy and s-phase in primary malignant melanoma as prognostic factors for stage iii disease.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968202/
https://www.ncbi.nlm.nih.gov/pubmed/8427773
work_keys_str_mv AT karlssonm dnaploidyandsphaseinprimarymalignantmelanomaasprognosticfactorsforstageiiidisease
AT boerydb dnaploidyandsphaseinprimarymalignantmelanomaasprognosticfactorsforstageiiidisease
AT carstensenj dnaploidyandsphaseinprimarymalignantmelanomaasprognosticfactorsforstageiiidisease
AT kagedalb dnaploidyandsphaseinprimarymalignantmelanomaasprognosticfactorsforstageiiidisease
AT bratelat dnaploidyandsphaseinprimarymalignantmelanomaasprognosticfactorsforstageiiidisease
AT wingrens dnaploidyandsphaseinprimarymalignantmelanomaasprognosticfactorsforstageiiidisease